HDAC8抑制靶向STAT3-MYC轴并与Venetoclax协同治疗KMT2A重排急性髓系白血病
该研究探讨HDAC8在KMT2A重排急性髓系白血病中的作用及靶向策略。研究发现HDAC8在KMT2A-r AML中高表达且与不良总生存相关;遗传敲除或药物抑制HDAC8可延缓白血病进展、延长生存并减少复发。机制上HDAC8抑制不依赖TP53状态下调STAT3-MYC轴,并与Venetoclax在原发性AML细胞及动物模型中协同抗白血病。
要点
- HDAC8在KMT2A-r AML中高表达,高HDAC8与不良总生存相关。
- HDAC8抑制可延缓白血病进展、延长生存并减少复发。
- HDAC8i与Venetoclax协同抗白血病,不依赖TP53状态。
核心结论
- HDAC8通过直接结合STAT3促进其去乙酰化与稳定,进而上调MYC,抑制HDAC8可降解STAT3并下调MYC。
- HDAC8抑制与Venetoclax联合在KMT2A-r AML模型中协同减少白血病负荷并显著延长生存。
研究设计与样本
- 研究采用KMT2A::MLLT3小鼠模型、原发性AML细胞及患者来源异种移植(PDX)模型。
- 方法包括HDAC8遗传敲除与药理学抑制(HDAC8选择性抑制剂),并结合生化实验分析HDAC8与STAT3相互作用。
主要发现
- HDAC8在KMT2A-r AML中表达上调,高HDAC8与KMT2A-r AML患者不良总生存相关。
- 在KMT2A::MLLT3小鼠模型中,HDAC8遗传敲除和药物抑制均显著延缓白血病进展、延长生存并减少疾病复发。
- HDAC8抑制不依赖TP53状态,在多种AML遗传亚型中下调STAT3-MYC轴。
- 生化实验显示HDAC8直接结合STAT3并促进其去乙酰化与稳定,HDAC8i处理导致STAT3乙酰化增加并降解,进而下调MYC。
- HDAC8i在原发性AML细胞中与Venetoclax表现出协同抗白血病活性,且不依赖TP53状态;联合治疗在KMT2A::MLLT3 AML和PDX模型中协同减少白血病负荷并显著延长生存。
临床怎么用
- 对于KMT2A重排AML,HDAC8高表达可作为不良预后参考指标。
- HDAC8选择性抑制剂与Venetoclax联合可能成为KMT2A-r AML的潜在治疗策略,且不受TP53状态限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML) is an aggressive AML subtype characterized by 11q23 chromosomal rearrangements involving KMT2A gene and clinically associated with poor prognosis. Herein, we show that HDAC8 is upregulated in KMT2A-r AML and high HDAC8 is associated with poor overall survival in KMT2A-r AML patients. Using a KMT2A::MLLT3 mouse model, we demonstrate that both genetic knockout and pharmacological inhibition of HDAC8 significantly delayed leukemia progression, prolonged survival and reduced disease recurrence. Mechanistically, HDAC8 inhibition downregulates STAT3-MYC axis independent of TP53 status across AML genetic subtypes. Biochemical assays revealed that HDAC8 binds directly to STAT3, promoting its deacetylation and stabilization, while HDAC8-selective inhibitor (HDAC8i) treatment results in increased STAT3 acetylation and subsequent STAT3 degradation which in turn downregulates MYC. Given that STAT3-MYC signaling promotes cell survival and Venetoclax resistance, we show that HDAC8i exhibits synergistic anti-leukemia activity with Venetoclax in primary AML cells regardless of TP53 status. Combination of HDAC8i and Venetoclax synergistically reduced leukemia burden and significantly prolonged survival in both KMT2A::MLLT3 AML and patient-derived xenograft models. This study highlights the regulatory function of HDAC8 on STAT3-MYC and provides the proof-of-principle for targeting HDAC8 in combination with Venetoclax for the treatment of KMT2A-r AML.
引用
- Zhang L, Guo W, Fu YH, et al. HDAC8 inhibition targets STAT3-MYC axis and synergizes with Venetoclax in KMT2A-rearranged acute myeloid leukemia. Leukemia. 2026. PMID: 42014858. doi:10.1038/s41375-026-02950-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。